COVID-19 disrupted cancer diagnosis timing, but lymphoma survival rates held steady
A Swedish study tracking 5,000+ lymphoma patients found that while pandemic lockdowns delayed diagnoses in spring 2020, overall cancer incidence and one-year survival rates remained unchanged through 2021. The findings suggest healthcare systems adapted quickly enough to prevent long-term survival gaps — a crucial benchmark for policymakers assessing pandemic resilience.
Originaltitel: Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival - a Swedish Lymphoma Register Study
<p>Background & purpose: The COVID-19 pandemic posed a large challenge for healthcare systems across the world. Comprehensive data on the impact of the COVID-19 pandemic on incidence and mortality in lymphoma are lacking.</p><p>Patients/methods: Using data from the Swedish lymphoma register, we compare incidence and 1-year survival of lymphoma patients in Sweden before (2017-2019) and during the pandemic (2020 and 2021).</p><p>Results: Fewer patients were diagnosed with lymphomas during March-June 2020, but the annual incidence rates for 2020 and 2021 were similar to those of 2017-2019. A larger proportion of patients presented with stage IV disease during 2021. There were no differences in other base-line characteristics nor application of active treatment in pre-pandemic and pandemic years. One-year overall survival was not inferior among lymphoma patients during the pandemic years compared to pre-pandemic years i.e., 2017-2019.</p><p>Interpretation: The COVID-19 pandemic had limited impact on the incidence and mortality of lymphoma in Sweden.</p>